

CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently amended) A cell line which synthesizes and expresses on the cell surface Thomsen-Friedenreich antigen (TF), mucin 1 (MUC1), and glycophorin.
2. (Cancelled)
3. (Previously presented) The cell line of claim 1 which is selected from the group consisting of
 - (a) a cell line denominated NM-F9 having the DSMZ accession number DSM ACC2606;
 - (b) a cell line denominated NM-D4 having the DSMZ accession number DSM ACC2605; and
 - (c) subclones of (a) or (b) which express on the cell surface TF, MUC1, and glycophorin.
4. (Cancelled)
5. (Previously presented) The cell line of claim 1, comprising a vector which comprises a nucleic acid molecule.
6. (Original) The cell line of claim 5, wherein said nucleic acid molecule encodes at least one polypeptide of a polypeptide selected from the group consisting of a cytokine, MHC class I molecule, MHC class II molecule and costimulatory molecule, T cell epitope or multimers thereof, tumour antigen, hormone, sexual

hormone, adjuvant, antibody or other molecules or fragments thereof having biological activity or any combination thereof.

7. (Withdrawn) A lysate, a molecule, or a mixture of molecules obtained from the cell line of claim 1.
8. (Cancelled)
9. (Withdrawn) Dendritic cells loaded with the lysate, the molecule, or the mixture of molecules of claim 7.
10. (Withdrawn) Dendritic cells co-incubated or fused with the cells of claim 1.
11. (Previously presented) A composition comprising
 - (a) a cell line which expresses on the cell surface TF, MUC1, and glycoporphin;
 - (b) a lysate, a molecule, or a mixture of molecules obtained from the cell line of (a);
 - (c) dendritic cells loaded with the lysate, the molecule, or the mixture of molecules of (b); or
 - (d) dendritic cells co-incubated or fused with the cells of (a).
12. (Previously presented) The composition of claim 11, which is a pharmaceutical or vaccine composition.
- 13-19. (Cancelled)

20. (Previously presented) A method for the treatment or prevention of cancers and/or tumourous diseases comprising administering a therapeutically or prophylactically effective amount of
- (a) a cell line which expresses on the cell surface TF, MUC1, and glycophorin;
 - (b) a lysate, a molecule, or a mixture of molecules obtained from the cell line of (a);
 - (c) dendritic cells loaded with the lysate, the molecule, or the mixture of molecules of (b);
 - (d) dendritic cells co-incubated or fused with the cells of (a); or
 - (e) the pharmaceutical or vaccine composition of claim 12.
21. (Cancelled)
22. (Previously presented) The method of claim 20, wherein said cancer or tumourous disease is a cancer of the head and neck, lung, mediastinum, gastrointestinal tract, genitourinary system, gynaecological system, breast, endocrine system, skin, childhood, unknown primary site or metastatic cancer, a sarcoma of the soft tissue and bone, a mesothelioma, a melanoma, a neoplasm of the central nervous system, a lymphoma, a leukaemia, a paraneoplastic syndrome, a peritoneal carcinomatosis, a immunosuppression-related malignancy and/or metastatic cancer.
23. (Previously presented) The cell line of claim 1, wherein the glycophorin is asialoglycophorin.

24. (Currently amended) The cell line of claim 1, wherein the MUC1 is tumor-associated MUC1 (TA-MUC1).